Table 1 Baseline characteristics and outcomes of study population according to vasopressor combination.
Variables | Norepinephrine + Epinephrine (n = 395) | Norepinephrine + Vasopressin (n = 506) | p-value |
|---|---|---|---|
Sex | |||
Men | 278 (70.4%) | 334 (66.0%) | 0.186 |
Women | 117 (29.6%) | 172 (34.0%) | |
Age (years) | 70 [57–79] | 70 [58–80] | 0.622 |
Calendar year | |||
2016–2019 | 139 (35.2%) | 59 (11.7%) | < 0.001 |
2020–2024 | 256 (64.8%) | 447 (88.3%) | |
Comorbidities | |||
Hypertension | 133 (33.7%) | 164 (32.4%) | 0.743 |
Diabetes | 105 (26.6%) | 138 (27.3%) | 0.876 |
Chronic heart disease | 68 (17.2%) | 79 (15.6%) | 0.579 |
Chronic lung disease | 21 (5.3%) | 36 (7.1%) | 0.336 |
Chronic kidney disease | 18 (4.6%) | 30 (5.9%) | 0.447 |
Stroke | 36 (9.1%) | 40 (7.9%) | 0.598 |
Malignancy | 33 (8.4%) | 87 (17.2%) | < 0.001 |
Prehospital variables | |||
Witness status | 280 (70.9%) | 344 (68.0%) | 0.388 |
Arrest place (public) | 94 (23.8%) | 84 (16.6%) | 0.009 |
Bystander CPR | 203 (51.4%) | 273 (54.0%) | 0.486 |
Shockable rhythm | 69 (17.5%) | 64 (12.6%) | 0.054 |
Prehospital defibrillation | 98 (24.8%) | 85 (16.8%) | 0.004 |
Prehospital advanced airway insertion | 336 (85.1%) | 453 (89.5%) | 0.056 |
In-hospital variables | |||
Total epinephrine dose (mg) | 6.4 ± 6.4 | 5.2 ± 4.7 | 0.001 |
CPR time (min) | 13 [7–28] | 13 [7–26] | 0.779 |
Lactate (mmol/L) | 11.7 [8.6–15.0] | 12.7 [9.9–15.4] | 0.002 |
CAG | 86 (21.8%) | 74 (14.6%) | 0.007 |
PCI | 14 (3.5%) | 31 (6.1%) | 0.107 |
TTM | 87 (22.0%) | 153 (30.2%) | 0.007 |
ECMO | 28 (7.1%) | 47 (9.3%) | 0.287 |
Survival outcomes | |||
Survival to discharge | 67 (17.0%) | 46 (9.1%) | 0.001 |
Good neurological outcome | 32 (8.1%) | 16 (3.2%) | 0.002 |
Survival at 6 month* | 26 (7.2%) | 7 (1.5%) | 0.001 |
Good neurological outcome at 6 month** | 17 (4.8%) | 4 (0.8%) | < 0.001 |
